

Index

A

Add-back therapy, 47
Abnormal uterine bleeding (AUB), 128
Absolute risks, 92
Adenocarcinomas, 64, 65
Adenomyosis, 157
 clinical features, 44, 45
 definition, 44, 45
 epidemiology, 44, 45
 etiopathogenesis, 45, 46
 risk factors, 45, 46
 treatment
 interventional procedures, 47
 nonsteroidal medical, 47
 steroidal, 46, 47
 surgical, 48
Adenomyosis-related symptoms, 47
Adverse effects (AEs), 90
Adverse risk, 94
American Society for Reproductive Medicine (ASRM), 108
Androgen insensitivity syndrome, 137, 138
Androgen receptor knockout (ARKO) mice, 19
Androgen therapy, 129
Androgens, 19, 20
Aneuploid, 28
Angiectasis, 150
Antiandrogens, 124, 126
Antiestrogenic effect, 172
Antiestrogens-like aromatase inhibitors, 127
Antifibrinolytics, 42
Anti-Mullerian hormone (AMH), 17
Antral follicle count (AFC), 15

Antral follicle pool
 androgens, 19, 20
 ectopic pregnancy, 26
 estrogen priming, 22
 fertilization, 26
 graafian follicles, 18
 growth hormone, 20, 21
 hypothalamus, 18
 individualized egg retrieval, 23, 25
 IVM, 23
 PGT, 28
 platelet-rich plasma, 21, 22
 rebound, 24, 25
 sex hormone deprivation, 18
Aromatase inhibitors (AIs), 47, 105
Atrophic endometrium, 60
Atrophic vaginal mucosa, 128
Atypical endometrial hyperplasia (AEH), 61

B

Basal follicle-stimulating hormone (b-FSH)
 age-specific testing, 16
 AMH, 17
 hypothalamic-pituitary response, 16
 ovarian sex steroids, 16
 ovulation induction, 17, 18
Bayesian network analysis, 99
Bidirectional communication, 23
Binary thinking, 121
Bioidentical hormone, 93
Blastocyst implantation, 69
Blood vessels, 5, 162, 168
Bone-mineral density (BMD), 93, 109

Breast atrophy, 128

Breast cancer, 172–175

C

Cancer screening, 129, 132

Cardiovascular disease (CVD), 113

Cardiovascular pathology, 125

Carotid artery intimal media thickness (CIMT), 96, 97

Cervical glands, 1

Clear cell carcinoma (CCC), 79, 82

Clonidine, 102

Coelomic epithelium, 1

Congenital sexual anomalies

adrenal insufficiency, 133

androgen insensitivity syndrome, 137, 138

classification, 132

correcting external genitalia, 133

embryo's development, 132

embryological development, 132

factors, 132

hormonal treatment, 133

Klinefelter syndrome, 137

matching the assigned gender, 133

Müllerian agenesis, 138–140

multidisciplinary approach, 133

patients, 134, 135

pubertal induction, 133, 134

screening mammography, 134

sex steroid hormones, 132

Turner syndrome and variants, 135, 136

uterine anomalies, 132

uterus, 133

Conjugated equine estrogen (CEE), 90, 91

Consecutive endometrial biopsies, 168

Controlled ovarian stimulation (COS), 17, 18

Coronary heart disease (CHD), 90

Cuboidal cells, 6

Cystic glands, 168

Cytoplasmic organelles, 10

Cytoreduction therapy, 70

D

Danazol, 47

Decidual cells, 6

Dehydroepiandrosterone (DHEA), 19, 20, 103

Denys–Drash syndrome, 133

Dienogest (DNG), 47

Disorder of sexual development (DSD), 132, 133

Dutasteride, 127

Dysmenorrhea, 45

Dyspareunia, 45

E

Early-onset group, 98

Early versus late intervention trial (ELITE), 97

Ectopic pregnancy, 26

Embolization for the Treatment of Symptomatic Uterine Fibroid Tumors study, 43

Embryo morphology, 27

Embryo transfer (ET), 26

Endocrinology, 104

Endometrial ablation, 43

Endometrial biopsy evaluation, 5

Endometrial carcinoma (EC)

classifications, 65

diagnosis, 68

etiology, 60

glandular architecture, 64

higher-grade tumors, 65

histologic types, 64, 65

histopathologic classification, 60

management

cytoreduction therapy, 70

hormone therapy, 70

radiation therapy, 70

surgical approaches, 69, 70

mortality, 59

multiple prognostic factors, 65

nuclear features, 64

obesity, 59

pathogenic types, 60

risk factors, 66–68

treatment, 62, 63, 69, 70

type I, 60, 63

type II, 60, 64

Endometrial dating, 2–4, 6

Endometrial glandular hyperplasia, 153

Endometrial hyperplasia, 60

clinical presentation, 62

diagnostic evaluation, 62

EIN, 62

management, 62, 63

nomenclature, 61

nuclear/cytoplasmic ratio, 61

progestin therapy, 61

surveillance, 62

Endometrial intraepithelial carcinoma (EIC), 60

Endometrial intraepithelial neoplasia (EIN), 60–62

Endometrial-myometrial junction, 44

Endometrial polyps (EPs), 158

clinical features, 48

definition, 48

epidemiology, 48

- etiopathogenesis, 48, 49
 - treatment, 49, 50
 - Endometrioid carcinoma (EC), 82
 - Endometrioid endometrial carcinomas (EEC), 81, 82
 - Endometrioid ovarian carcinomas (EOC), 81, 82
 - Endometriosis
 - diagnosis, 74
 - epigenetic, 79
 - gynecologic disease, 73
 - histology, 74, 77, 79
 - hormonal influences, 73
 - hormonal-related cyclic changes, 73
 - inflammatory reaction, 73
 - microenvironment and immune system, 79–81
 - ovarian cancer (*see* Ovarian cancer)
 - ovarian endometriotic foci, 74
 - pathogenesis, 74
 - treatment, 80, 81
 - Endometriosis-associated ovarian cancer (EAOC), 74
 - Endometriosis-associated ovarian carcinoma (EAOC), 82, 83
 - Epidermal growth factor (EGF), 41
 - Epithelial cells, 5
 - Estrogen-agonist effect, 172, 174
 - Estrogen alone, unopposed by progesterone (ERT), 159, 161
 - Estrogen and thromboembolism risk (ESTHER), 109
 - Estrogen deficiency, 22
 - Estrogen plus progestin (EPT), 92
 - Estrogen priming, 22
 - Estrogen–progestogen (EPT), 11, 89
 - Estrogen receptor (ER), 79
 - Estrogen replacement therapy (ERT), 159
 - Estrogens, 68, 89, 123–128, 133, 136, 138, 140
 - Estrogen therapy, 67
 - clonidine, 102
 - Gabapentin (GABA), 101
 - paroxetine (paxil), 101
 - tamoxifen, 101
 - VMS, 100
 - Etiopathogenesis, 45
 - Euploid biopsy, 28
 - European Menopause and Andropause Society (EMAS), 109
 - European Society of Human Reproduction and Embryology (ESHRE), 108–109
 - Extracellular matrix (ECM), 38
- F**
- Female Sexual Function Inventory (FSFI), 97
 - Female-to-male type (FTM), 127
 - Feminizing hormone therapy, 125
 - Fertility issues, 140
 - Fertilization, 26
 - Fibrin thrombi, 6
 - Fibroblasts, 106
 - FIGO classification system, 38
 - Final menstrual period (FMP), 89
 - Finasteride, 127
 - First pass effect, 112
 - Flow-mediated dilation (FMD), 111
 - Fluorescence in situ hybridization (FISH), 28
 - Follicle selection phase (FSH), 3
 - Follicle-stimulating hormone (FSH), 3, 147, 152
 - Fumarate hydratase (FH), 41
 - Functional ovarian reserve (FOR), 15
- G**
- Gabapentin (GABA), 101
 - Gallbladder disease, 90
 - Gender-affirming therapy, 123
 - Gender dysphoria, 122–125, 137, 140
 - Gender fluidity, 121
 - Gender identity, 121, 122
 - Gene polymorphisms, 45
 - Genetic and epigenetic factors, 40
 - Genetics, 60, 74, 82, 83
 - Genitourinary syndrome of menopause (GSM), 89, 102–103
 - DHEA, 103
 - estrogen, 103
 - moisturizers and lubricants, 103
 - ospemiphene, 103
 - Germline stem cells (GSCs), 22
 - Glandular epithelium, 168
 - Glandular hyperplasia, 173
 - Gonadoblastoma, 134, 135
 - Gonadotropin-releasing hormones (GnRH), 42, 63, 125, 147, 152, 155
 - Gonadotropins, 2, 3, 17
 - Graafian follicles, 17
 - Granulosa cell molecular function, 23
 - Growth hormone, 20, 21
- H**
- Heart and Estrogen Replacement Study (HERS), 91–92
 - Heat shock response, 105

- Hereditary leiomyomatosis and renal cancer syndrome (HLRCC), 41
- High-dose progestins, 168
- High-grade histology, 66
- High-grade malignant tumors, 67
- High mobility group (HMG) family, 48
- Hormonal contraception, 147
- Hormonal contraceptive therapy
- adenomyosis, 157
 - blood vessels, 150
 - cervical mucus density, 147
 - contraceptive endometrium, 150
 - cytoplasm, 148
 - endocervical microglandular hyperplasia, 151
 - endometrial histology, 149
 - endometrial hyperplasia, 147
 - endometrial microscopic, 148
 - endometrial polyps, 158
 - endometrial tissue, 148
 - estrogen and progesterone/progestin, 147
 - gestational purposes, 150
 - histologic patterns, 151
 - infertility, 151–154
 - leiomyomas, 155–157
 - menstrual shedding, 151
 - metabolic disturbances, 148
 - neoplasia, 147
 - ovulation suppression, 147
 - predominant effect, 148
 - PRM, 151
 - spiral arterioles, 150
 - uterine tissue, 148
- Hormonal effects
- biological functions, 13
 - infertility, 13
 - mRNA expression, 24
 - reproductive processes, 13
 - sexual intercourse, 13
- Hormone receptors
- estrogen, 68, 69
 - progesterone, 69
- Hormonal-related cyclic changes, 73
- Hormone replacement therapy, 11, 67, 89, 158
- Hormone-sensitive malignancy, 124
- Hormone therapy (HT), 70, 110, 146
- cancer screening, 129, 132
 - definitions, 122
 - feminizing, 123, 124
 - gender-affirming, 124
 - gender identity, 121
 - guidelines, 124
 - masculinizing, 124
 - primary medical intervention, 123
 - therapeutic approaches, 123
 - transgender female, 125–127
 - transgender male, 127–130
- Human mammary tumor virus (HMTV), 60
- Hypergonadotropism persists, 8
- Hypoactive sexual desire disorder (HSDD), 97
- Hypoparathyroidism, 90
- Hysterectomy, 48, 59, 69, 168
- Hysteroscopic excision, 48
- Hysteroscopic resection, 42
- I**
- Iatrogenic hormone therapy, 6
- In vitro maturation of immature oocytes (IVM), 23
- Infertility, 13
- AFC, 15
 - male factor, 14
 - ovarian reserve, 14, 15
- International Federation of Gynecology and Obstetrics (FIGO), 61, 64, 66, 67
- International Menopause Society (IMS), 109, 114
- International Society for the Study of Women's Sexual Health (ISSWSH), 102
- Intracrinology, 104
- Intrauterine devices (IUD), 156
- K**
- Kisspeptin/neurokinin B/dynorphin group (KNDy), 100
- Klinefelter syndrome, 137
- Kronos Early Estrogen Prevention Study (KEEPS), 96
- L**
- Laparoscopy, 69
- Later-onset group, 98
- Leiomyoma
- clinical features, 38, 40
 - definition, 38, 40
 - epidemiology, 38, 40
 - etiopathogenesis, 40, 41
 - risk factors, 40, 41
 - treatment
 - hysteroscopic resection, 42
 - interventional procedures, ULs, 43
 - medical, 42
 - randomized controlled trials, 41
 - surgical, 42, 43

- Leiomyomas, 155–157
 Leptin, 2
 Levonorgestrel intrauterine device (LNG-IUD), 42, 47
 Low-density lipoprotein (LDL), 95
 Luteinizing hormone (LH), 147, 152
 Lymph node assessment, 66
 Lymph node metastasis, 70
 Lymph nodes, 60
 Lynch syndrome, 60
- M**
 Magnetic resonance-guided focused ultrasound (MRgFUS), 43
 Male factor, 14
 Male-to-female type (MTF), 125
 Malignant mixed Mullerian tumors, 173
 Masculinizing hormone therapy, 127
 Maternal hormonal influence, 1
 Matrix metalloproteinases (MMP), 95
 Medroxyprogesterone acetate (MPA), 89, 91, 168
 Menopausal hormone therapy (MHT)
 colorectal cancer, 112
 contraindications, 90
 indications, 89
 joint and muscles, 111
 metabolism, 112
 primary prevention of CVD, 114
 progestins, 89
 progestogens, 89
 timing hypothesis, 96
 VSM, 114
 Menopause, 7, 10, 11, 89
 Menstruation-suppression therapies, 127
 Microfibrils (fibrillogenesis), 106
 Micronized progesterone (MP), 113
 Mid-proliferative endometrium, 6, 7
 Mild inflammatory infiltrates, 153
 Mild vasomotor group, 98
 Minimally invasive surgical procedures, 48
 Molecular pathways, 80
 Monoamine oxidase (MAO), 101
 Morphological findings, 107
 MRI-guided focused ultrasound (MRgFUS), 47
 Müllerian agenesis, 138–140
 Müllerian aplasia/Mayer–Rokitansky–Küster–Hauser syndrome (MRKH syndrome), 138
 Müllerian inhibiting substance (MIS), 1
 Myolysis, 43
 Myomatous nodules, 156
 Myomectomy, 43
 Myometrial invasion, 66
 Myometrium, 41
- N**
 National Swedish Cancer Registry, 75
 Necrosis, 156
 Neurokinin B (NKB), 100
 Nonsteroidal anti-inflammatory drugs (NSAIDs), 42, 47
 Norethisterone acetate (NETA), 47
 North American Menopause Society (NAMS), 102, 159
 Nucleoli, 5
- O**
 Obesity, 59
 Oocytes, 136
 Oral contraception (OC), 147
 Ospemiphene, 103
 Osteoporosis, 107–108
 Ovarian cancer
 ARID1A, 78
 clear cell carcinoma, 74
 EAOC, 74
 early diagnosis and long-standing endometriosis, 75
 epidemiologic studies, 76, 77
 epithelial, 77
 gene mutations, 78
 histopathologic studies, 77
 non-Hodgkin lymphoma, 75
 postmenopausal women, 75
 primary infertility, 75
 PTEN mutation, 78
 reciprocal analysis, 77
 TP53 mutation, 78
 type I tumors, 78
 type II tumors, 78
 Ovarian Cancer Association Consortium
 database, 77
 Ovarian hyperstimulation syndrome, 15
 Ovarian hyperthecosis, 48
 Ovarian insufficiency, 21
 Ovotestis, 134
 Ovulation, 2, 3, 5, 6
- P**
 Pathogenetic factors, 40
 Pelvic and para-aortic lymphadenectomy, 69
 Perimenopausal irregular vaginal bleeding, 10

- Peritoneal cavity, 66
 Pituitary-ovarian system, 2
 Platelet-rich plasma (PRP), 21, 22
 Polycystic ovarian disease (PCOD), 129, 153
 Polycystic ovary, 131
 Postmenopausal Estrogen/Progestin Intervention (PEPI) Trial, 91
 Postmenopausal symptoms, 146
 Postovulatory endometrium, 8
 Predominant estrogen effect, 163
 Preimplantation genetic diagnosis (PGD), 28
 Preimplantation genetic testing (PGT), 28
 Premature ovarian insufficiency (POI), 109
 Primary ovarian insufficiency (POI)
 autoimmune, 108
 endometrial protection, 109
 estrogen deficiency, 108
 extension therapy, 108
 genetic, 108
 GSM, 108
 iatrogenic, 108
 menstrual cycle, 109
 PEPI group, 109
 premature menopause, 108
 psychological impact, 110
 replacement therapy, 108
 VTE, 109
 Progesterone, 41, 69, 126, 127, 133, 136, 138, 140
 Progesterone receptor, 42
 Progesterone receptor modulators (PRM), 151, 157
 Progesterone therapy, 168, 170, 171
 Progestin therapy, 63
 Progestins, 89
 Progestogens, 126
 Proliferative and secretory patterns, 162
 Proliferative endometrium, 3, 5
 Pseudomenstrual changes, 163
 Pseudopregnancy, 171
 Psychosocial counseling, 139
 Psychotherapy, 123
- R**
 Radiation therapy, 70
 Reactive oxidative species (ROS), 79, 80
 Redox imbalance, 79
 Replacement hormonal therapy, 133
 Retroperitoneal lymph nodes, 66
- S**
 Salpingo-oophorectomy, 69
 SART grading system, 27
- Scanning electron microscopy, 9, 10
 Secretory endometrium, 10
 Selective estrogen receptor modulators (SERMs), 43, 47, 59, 127
 Selective progesterone receptor modulators (SPRMs), 42, 47
 Sentinel event, 111
 Sentinel lymph node evaluation, 69
 Sex-determining region on the Y chromosome gene (SRY gene), 132
 Sex-hormone-binding globulin (SHBG), 97
 Sexual orientation, 122
 Signaling pathways, 41
 Spiral arterioles, 5, 6, 10, 11
 Standardized incidence ratios (SIRs), 75
 Statin therapy, 114
 Stem cells, 41
 Steroid hormones, 146
 Streak gonads, 136
 Stromal cells, 5
 Study of Women's Health Across the Nation (SWAN), 98
 Super Flasher group, 98
 Surgical interventions, 123
 Swedish Inpatient Registry, 75
- T**
 Tamoxifen, 45, 49, 50, 67, 146, 172–174
 Testosterone, 124, 126, 128
 Thermoneutral zone (TNZ), 99
 Thromboembolic disease, 90
 Thrombosis, 150
 Timing hypothesis, 115
 atherosclerosis, 95
 bedrock principle, 98
 CIMT, 97
 ELITE, 97
 exogenous estrogen, 95
 postmenopause, 96
 sexual function, 97
 Tissue injury and repair (TIAR)
 mechanism, 45
 Transcervical resection (TCRP), 50
 Transgender, 122
 Transmission electron microscopic image, 9
 Trophectoderm, 27
 True hermaphrodites, 135
 Tubal disease, 26
 Turner syndrome and variants, 135, 136
- U**
 Ulipristal acetate (UPA), 42
 Urinary tract infections (UTIs), 102

- U.S. Preventive Services Task Force (USPSTF), 114
- Uterine adnexa, 66
- Uterine artery embolization (UAE), 43, 47
- Uterine leiomyomas (ULs), 38
- Uterine transplants, 140
- Uterus
- abnormal hormonal stimulation, 146
 - adolescents and young women, 146
 - benign lesions, 146
 - biologic activity, 146
 - complex interplay, 145
 - congenital anomalies, 1
 - diversity, 146
 - effects of combined HRT, 162–164
 - effects, ERT, 159, 161
 - endometrial biopsies, 146
 - endometrial cyclic changes
 - basal glands, 3
 - epithelial and stromal cells, 3
 - estradiol, 3
 - gonadotropin releases, 3
 - hormonal influences, 2
 - menstrual blood flow, 3
 - microscopic pattern, 6
 - mitotic activity, 5
 - myometrium, 3
 - progesterone, 3
 - spiral arterioles, 5
 - vaginal cavity, 2
 - endometrium, 1, 145
 - estrogens and estrogen derivatives, 158
 - GnRH pulse generator, 2
 - gonadotropins, 2
 - gonad-secreted hormones, 145
 - hormonal contraceptive therapy (*see* Hormonal contraceptive therapy)
 - hormone therapy, 146
 - HRT, 158
 - immunohistologic markers, 147
 - menarche, 2
 - menopause, 7, 10, 11
 - microscopic analysis, 146
 - Müllerian duct development, 1
 - normal reproduction, 145
 - physiological and pathological hormonal influences, 147
 - postmenopausal morbidity, 158
 - promptitude and versatility, 145
 - receptor-bound hormone, 145
 - steroid receptor functions, 145
 - tamoxifen, 172–174
- V**
- Vaginal DHEA (Prasterone)
- endocrinology, 104
 - GSM, 103
 - intracrinology, 104
- Vaginal Erbium YAG lasers (VEL), 106
- Vaginal laser, 105, 106
- Vaginal mucosa, 107
- Vaginal testosterone, 104
- Vasomotor symptoms (VMS), 89
- cardiovascular disease, 110–111
 - follicle-stimulating hormone, 99
 - HF, 99
 - menopause transition, 98
 - patterns/trajectories, 98
 - physiology, 99–100
 - post-traumatic stress, 99
 - psychosocial impairment, 98
 - symptom, 98
- Venous thromboembolism (VTE), 92, 103, 109, 112
- Vulvovaginal atrophy (VVA), 89
- W**
- Women Health Initiative (WHI), 158
- CHD, 92
 - clinical consequences, 93–94
 - EPT, 92
 - intention, 92
- Women's Ischemia Syndrome Evaluation (WISE), 110
- World Professional Association for Transgender Health (WPATH), 123